Epstein Secrets

cals business from 2000 to 2003. Prior to joining SmithKline Beecham plc Mr. Pien worked for six years at Abbott Laboratories and for five years at Merck & Co. Mr. Pien is also a director of Vanda Pharmaceuticals and ViroPharma Incorporated. DACART CAPITAL LLC EFTA_R1_01138848 EFTA02295574 References

ITAL LLC EFTA_R1_01138807 EFTA02295533 The Case for Investment • Investment opportunities identified • First 4 investments are teed up • Short time & limited capital to profit/liquidity • Managing Director's hands-on involvement • Competitive fees - 2%/20% DAC..., CAPITAL Li_c EFTA_R1_01138808 EFTA02295534

cals business from 2000 to 2003. Prior to joining SmithKline Beecham plc Mr. Pien worked for six years at Abbott Laboratories and for five years at Merck & Co. Mr. Pien is also a director of Vanda Pharmaceuticals and ViroPharma Incorporated. DACAR 1 CAPIIAL LLC EFTA00506153 References • Michael Eisenso

AR I C API JAL LLC7 • r EFTA00506112 The Case for Investment ■ Investment opportunities identified ■ First 4 investments are teed up • Short time & limited capital to profit/liquidity ■ Managing Director's hands-on involvement • Competitive fees - 2%/20% DACARTGAPIIAL LLC, EFTA00506113 The Case for Invest

cals business from 2000 to 2003. Prior to joining SmithKline Beecham plc Mr. Pien worked for six years at Abbott Laboratories and for five years at Merck & Co. Mr. Pien is also a director of Vanda Pharmaceuticals and ViroPharma Incorporated. DACAR 1 CAPIIAL LLC EFTA00506199 Advisory Board Andreas Breme

nt. DACAR1 LLC: EFTA00506161 The Case for Investment • Investment opportunities identified • First 5 investments are ready, 3 backups • Short time & limited capital to profit/liquidity • Managing Director's hands-on involvement • Competitive fees — 2%/20% DACART CAPIIAL LLCL EFTA00506162 The Case for Invest